ZA201205425B - Treatment with vb-201 - Google Patents
Treatment with vb-201Info
- Publication number
- ZA201205425B ZA201205425B ZA2012/05425A ZA201205425A ZA201205425B ZA 201205425 B ZA201205425 B ZA 201205425B ZA 2012/05425 A ZA2012/05425 A ZA 2012/05425A ZA 201205425 A ZA201205425 A ZA 201205425A ZA 201205425 B ZA201205425 B ZA 201205425B
- Authority
- ZA
- South Africa
- Prior art keywords
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29222610P | 2010-01-05 | 2010-01-05 | |
| US28225010P | 2010-01-07 | 2010-01-07 | |
| US35197510P | 2010-06-07 | 2010-06-07 | |
| US38931810P | 2010-10-04 | 2010-10-04 | |
| US42311210P | 2010-12-15 | 2010-12-15 | |
| PCT/IL2011/000008 WO2011083465A1 (en) | 2010-01-05 | 2011-01-05 | Treatment with vb-201 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201205425B true ZA201205425B (en) | 2015-07-29 |
Family
ID=44305239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2012/05425A ZA201205425B (en) | 2010-01-05 | 2012-07-19 | Treatment with vb-201 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20120329758A1 (enExample) |
| EP (2) | EP2521454A4 (enExample) |
| JP (2) | JP2013516457A (enExample) |
| KR (1) | KR20120133375A (enExample) |
| CN (1) | CN102834011B (enExample) |
| AU (1) | AU2011204406B2 (enExample) |
| BR (1) | BR112012016543A2 (enExample) |
| CA (1) | CA2786060A1 (enExample) |
| ES (1) | ES2654944T3 (enExample) |
| MX (1) | MX2012007807A (enExample) |
| NZ (1) | NZ601224A (enExample) |
| WO (3) | WO2011083469A1 (enExample) |
| ZA (1) | ZA201205425B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| US7807847B2 (en) | 2004-07-09 | 2010-10-05 | Vascular Biogenics Ltd. | Process for the preparation of oxidized phospholipids |
| US9006217B2 (en) | 2007-01-09 | 2015-04-14 | Vascular Biogenics Ltd. | High-purity phospholipids |
| US8569529B2 (en) | 2007-01-09 | 2013-10-29 | Vascular Biogenics Ltd. | High-purity phospholipids |
| EP2348864A4 (en) * | 2008-10-08 | 2013-07-31 | Vascular Biogenics Ltd | OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF |
| EP2826370A3 (en) | 2008-11-06 | 2015-04-08 | Vascular Biogenics Ltd. | Oxidized lipid compounds and uses thereof |
| CA2847218C (en) * | 2011-09-01 | 2018-02-27 | Vascular Biogenics Ltd. | Formulations and dosage forms of oxidized phospholipids |
| ES2758923T3 (es) * | 2011-12-12 | 2020-05-07 | Vascular Biogenics Ltd | Tratamiento de esteatohepatitis no alcohólica |
| EP2814497A4 (en) * | 2012-02-16 | 2015-12-09 | Vascular Biogenics Ltd | METHOD FOR TREATING PSORIASIS AND VESSEL IGNITION |
| US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
| EP3223824B1 (en) | 2014-11-26 | 2021-01-06 | Vascular Biogenics Ltd. | Oxidized lipids and treatment or prevention of fibrosis |
| US9771385B2 (en) | 2014-11-26 | 2017-09-26 | Vascular Biogenics Ltd. | Oxidized lipids |
| WO2017173203A1 (en) * | 2016-03-31 | 2017-10-05 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing intestinal permeability |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6838452B2 (en) * | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| WO2002041827A2 (en) * | 2000-11-24 | 2002-05-30 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| PL1773352T3 (pl) * | 2004-07-09 | 2014-04-30 | Vascular Biogenics Ltd | Ulepszony sposób wytwarzania utlenionych fosfolipidów |
| US8084209B2 (en) * | 2005-07-22 | 2011-12-27 | Children's Hospital & Research Center Oakland | HMGCR isoforms in prediction of efficacy and identification of cholesterol-modulating compounds |
| US20090074720A1 (en) * | 2005-10-28 | 2009-03-19 | Sabbadini Roger A | Methods for decreasing immune response and treating immune conditions |
| US8137977B2 (en) * | 2006-04-24 | 2012-03-20 | Children's Hospital & Research Center At Oakland | Lipidomic approaches to determining drug response phenotypes in cardiovascular disease |
| CA2702437C (en) * | 2007-11-28 | 2013-06-25 | Teva Pharmaceutical Industries Ltd. | Method of delaying the onset of clinically definite multiple sclerosis |
-
2011
- 2011-01-05 JP JP2012547588A patent/JP2013516457A/ja active Pending
- 2011-01-05 CA CA2786060A patent/CA2786060A1/en not_active Abandoned
- 2011-01-05 CN CN201180009408.XA patent/CN102834011B/zh not_active Expired - Fee Related
- 2011-01-05 ES ES11731736.2T patent/ES2654944T3/es active Active
- 2011-01-05 AU AU2011204406A patent/AU2011204406B2/en not_active Ceased
- 2011-01-05 WO PCT/IL2011/000012 patent/WO2011083469A1/en not_active Ceased
- 2011-01-05 BR BRBR112012016543-7A patent/BR112012016543A2/pt not_active IP Right Cessation
- 2011-01-05 WO PCT/IL2011/000010 patent/WO2011083467A1/en not_active Ceased
- 2011-01-05 EP EP11731734.7A patent/EP2521454A4/en not_active Withdrawn
- 2011-01-05 KR KR1020127020564A patent/KR20120133375A/ko not_active Withdrawn
- 2011-01-05 US US13/520,713 patent/US20120329758A1/en not_active Abandoned
- 2011-01-05 NZ NZ60122411A patent/NZ601224A/en not_active IP Right Cessation
- 2011-01-05 US US13/520,719 patent/US20130172294A1/en not_active Abandoned
- 2011-01-05 WO PCT/IL2011/000008 patent/WO2011083465A1/en not_active Ceased
- 2011-01-05 MX MX2012007807A patent/MX2012007807A/es not_active Application Discontinuation
- 2011-01-05 JP JP2012547586A patent/JP2013516455A/ja active Pending
- 2011-01-05 EP EP11731736.2A patent/EP2521569B1/en active Active
-
2012
- 2012-07-19 ZA ZA2012/05425A patent/ZA201205425B/en unknown
-
2013
- 2013-03-14 US US13/828,643 patent/US20130225525A1/en not_active Abandoned
-
2015
- 2015-02-13 US US14/622,093 patent/US20160008381A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2521569B1 (en) | 2017-11-01 |
| EP2521569A1 (en) | 2012-11-14 |
| AU2011204406A1 (en) | 2012-08-02 |
| KR20120133375A (ko) | 2012-12-10 |
| EP2521454A4 (en) | 2013-06-26 |
| WO2011083469A1 (en) | 2011-07-14 |
| WO2011083467A1 (en) | 2011-07-14 |
| CN102834011B (zh) | 2016-01-13 |
| CN102834011A (zh) | 2012-12-19 |
| US20130225525A1 (en) | 2013-08-29 |
| EP2521454A1 (en) | 2012-11-14 |
| NZ601224A (en) | 2015-03-27 |
| CA2786060A1 (en) | 2011-07-14 |
| US20130172294A1 (en) | 2013-07-04 |
| JP2013516455A (ja) | 2013-05-13 |
| US20120329758A1 (en) | 2012-12-27 |
| AU2011204406B2 (en) | 2015-05-07 |
| WO2011083465A1 (en) | 2011-07-14 |
| ES2654944T3 (es) | 2018-02-15 |
| BR112012016543A2 (pt) | 2015-09-01 |
| EP2521569A4 (en) | 2013-05-22 |
| JP2013516457A (ja) | 2013-05-13 |
| MX2012007807A (es) | 2012-10-03 |
| US20160008381A1 (en) | 2016-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2652193T3 (pl) | Obróbka | |
| IL222481A0 (en) | Combination therapy | |
| EP2552323A4 (en) | COMBINATION THERAPY | |
| PL2621569T3 (pl) | Urządzenie lecznicze | |
| ZA201205425B (en) | Treatment with vb-201 | |
| PH12013500022A1 (en) | Surface treatment | |
| EP2641891A4 (en) | PKC ACTIVATOR- | |
| EP2560677A4 (en) | COLD TREATMENT | |
| GB201013573D0 (en) | Treatment | |
| GB201005394D0 (en) | Therapy | |
| ZA201308117B (en) | Avian-based treatment | |
| GB201014097D0 (en) | Treatment | |
| EP2629766A4 (en) | COMBINATION THERAPY | |
| GB201102283D0 (en) | Treatment | |
| GB201021319D0 (en) | Treatment | |
| GB2483219B (en) | Surface Treatment | |
| GB201007488D0 (en) | Treatment regime | |
| GB201007429D0 (en) | Treatment regime | |
| GB201001670D0 (en) | Use | |
| GB201010836D0 (en) | Easy squeezy | |
| GB201102266D0 (en) | Treatment | |
| GB201111247D0 (en) | Treatment | |
| GB201102284D0 (en) | Treatment | |
| GB201109119D0 (en) | Treatment | |
| GB201102282D0 (en) | Treatment |